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Further analysis of the sequencing reads originally interpreted as supporting the presence of a SF3B1 K700Emutation in patient 14
has established that these were of too low quality to call this mutation, and therefore this patient should instead have been catego-
rized as ‘‘del(5q) only.’’ Importantly, while this error changes themutational status of patient 14 (see the corrected Figures 4A, 4B, and
5A–5C below), it does not impact the main conclusions drawn from Figures 4 and 5 (neither overall, nor for patient 14), namely that all
detected genomic lesions originate from the MDS stem cell compartment and that the acquisition of del(5q) is predicted to precede
acquisition of other recurrent DNA mutations.
The change of patient 14 to a ‘‘del(5q) only’’ patient also results in minor changes to data referenced in the text and Supplemental
Information as follows:
The total number of genetic lesions identified in the analyzed patients changed from 34 to 33 lesions (page 798, right column, first
paragraph).
Mean variant allele frequency (VAF) in whole bonemarrow changed from 30.8% (±3.3%) to 32.0% (±3.2%) (page 799, left column,
first paragraph).
Mean VAF in LinCD34+CD38CD90+CD45RA SC compartment changed from 43.4% (±4.2%) to 44.8% (±4.1%) (page 799,
right column, first paragraph).
Number of ‘‘del(5q) only’’ patients in the targeted re-sequenced cohort changed from 19 (36%) to 20 (38%) (page 801, left column,
second paragraph).
Frequency of confident prediction for del(5q) preceding a recurrent driver mutation changed from 12 of 16 cases to 11 of 15 cases
(page 801, right column, first paragraph).
Data related to the SF3B1 mutation for patient 14 in Tables S1, S2, and S3 should be disregarded.Cancer Cell 27, 603–605, April 13, 2015 ª2015 Elsevier Inc. 603
Figure 4. Mapping of Somatic Genetic Lesions to Rare and Distinct MDS Stem Cells
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Figure 5. With Exception of SF3B1-Mutated Cases with Ring Sideroblasts, del(5q) Precedes Recurrent Driver Mutations in Low- to Interme-
diate-Risk MDS
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